Minervax ApS: Clinical Trials

5 trials sponsored by Minervax ApS, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting, 1 not yet recruiting, 1 withdrawn. 5 Phase 2, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Completed 2, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1
Phase 33Active not recruiting 1, Not yet recruiting 1, Withdrawn 1

Follow Minervax ApS: new trials by email

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
GBS-NN/NN2 vaccine, Placebo - Streptococcus Agalactiae Infection, Neonatal Sepsis
Phase 2 / Phase 3Not yet recruitingMinervax ApS66002026-11-302026-11-06
A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women
GBS-NN/NN2 vaccine - Streptococcus Agalactiae Infection, Neonatal Sepsis
Phase 2 / Phase 3Active not recruitingMinervax ApS1372025-03-072026-09-04
GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age
GBS-NN/NN2 vaccine, Tdap vaccine, Placebo - Streptococcus Agalactiae Infection
Phase 2 / Phase 3WithdrawnMinervax ApS2024-12-172026-10-13
Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women
GBS-NN/NN2 Vaccine, Placebo - Group B Streptococcal Infection
Phase 2CompletedMinervax ApS2692022-02-172025-06-11
Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV
GBS-NN/NN2, Placebo - Group B Streptococcal Infection
Phase 2CompletedMinervax ApS2002020-11-192026-07-14

Conditions studied

Streptococcal Infections (5)  ·  Meningitis (2)  ·  Neonatal Sepsis (2)  ·  Pneumonia (2)  ·  Bacterial Infections (1)  ·  Bacterial Infections and Mycoses (1)  ·  Gram-Positive Bacterial Infections (1)  ·  Infections (1)

Interventions

Boostrix (1)  ·  Saline Solution (1)

Countries

South Africa (3)  ·  Denmark (2)  ·  Uganda (1)  ·  United Kingdom (1)

Top investigators

Cornelia Oostvogels (2)  ·  Jeannett Dimsits (1)

Results publications

PMID 38190492, PMID 41386262

NIH funding

2023 (1)